These data are apparently contrasting with previous studies reporting that IL-17A levels <6.26 pg/ml in serum are related to a higher risk of post-infarction mortality; at this point, the only death recorded in the present cohort coincided with the highest serum concentration of IL 17A (Simon et al., 2013). Here, IL17A is linked to infarction.